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Abstract
Background: EphrinA5 is one of the best-studied members of the Eph-ephrin family of guidance molecules,
known to be involved in brain developmental processes. Using in situ hybridization, ephrinA5 mRNA expression
has been detected in the retinotectal, the thalamocortical, and the olfactory systems; however, no study focused
on the distribution of the protein. Considering that this membrane-anchored molecule may act far from the
neuron soma expressing the transcript, it is of a crucial interest to localize ephrinA5 protein to better understand
its function.
Results: Using immunohistochemistry, we found that ephrinA5 protein is highly expressed in the developing
mouse brain from E12.5 to E16.5. The olfactory bulb, the cortex, the striatum, the thalamus, and the colliculi
showed high intensity of labelling, suggesting its implication in topographic mapping of olfactory, retinocollicular,
thalamocortical, corticothalamic and mesostriatal systems. In the olfactory nerve, we found an early ephrinA5
protein expression at E12.5 suggesting its implication in the guidance of primary olfactory neurons into the
olfactory bulb. In the thalamus, we detected a dynamic graduated protein expression, suggesting its role in the
corticothalamic patterning, whereas ephrinA5 protein expression in the target region of mesencephalic
dopaminergic neurones indicated its involvement in the mesostriatal topographic mapping. Following E16.5, the
signal faded gradually and was barely detectable at P0, suggesting a main role for ephrinA5 in primary molecular
events in topographic map formation.
Conclusion: Our work shows that ephrinA5 protein is expressed in restrictive regions of the developing mouse
brain. This expression pattern points out the potential sites of action of this molecule in the olfactory, retinotectal,
thalamocortical, corticothalamic and mesostriatal systems, during development. This study is essential to better
understand the role of ephrinA5 during developmental topographic mapping of connections and to further
characterise the mechanisms involved in pathway restoration following cell transplantation in the damaged brain.
Background
Ephrins are ligands for transmembrane Eph-receptors,
the largest group of receptor tyrosine kinases, that have
been shown to be implicated in various developmental
mechanisms such as cell adhesion, cell migration,
boundary formation, axonal pathӿnding, axon guidance,
layer-speciӿc arborisations, target area, topographic
mapping and apoptosis [1-5]. A total of 9 members have
been identified to date and are divided into two sub-
families consisting of 6 ephrinA (A1-A6) and 3 ephrinB
(B1-B3) ligand types [5]. EphrinA and B differ in their
membrane-anchorage and on their receptor affinity:
ephrinA are glycosylphosphatidylinositol (GPI)-linked
proteins and bind generally to the EphA-receptors,
whereas ephrinB have a transmembrane domain and a
cytoplasmic region, and interact preferentially with
EphB-receptors. Exceptions in the binding discrimina-
tion between classes are that ephrinA5, at high concen-
tration, can bind to EphB2 [6], and ephrinB-ligands to
EphA4 [7]. Ephrins and their receptors are highly
expressed in the developing nervous system and often in
complementary gradients inside delimited regions of the
central nervous system [8,9]. This feature is particularly
well described in the retinotectal system, where graded
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ordered retinocollicular projection: temporal retinal
axons, which express high levels of EphA-receptors,
terminate in a low ephrin expression region of the tec-
tum (the anterior part), whereas, nasal axons, which
exhibit a low Eph-receptor expression, connect to the
posterior tectum, which is a high ephrinA expression
region [10].
Within the ephrinA group, ephrinA5 has been exten-
sively studied and was shown to be a ligand for EphA3
[11,12], EphA4 [13,14], EphA5 [10], EphA7 [15] and
EphB2 [6] receptors. The study of its expression, mainly
explored at the mRNA level in the rodent developing
brain, has shown that ephrinA5 is present from early
organogenesis [16] to postnatal stages throughout the
central nervous system. In the telencephalon, ephrinA5
mRNA is expressed in the olfactory system [17,18], in
the lateral and medial ganglionic eminences and their
ventricular zones [19-21] and in the cortex [22-27].
EphrinA5 transcript expression has been also detected
in the diencephalon (hypothalamus and thalamus)
[10,21,27-29] and in the inferior and superior colliculi as
well as in the pretectal nuclei and the red nucleus of the
mesencephalon [28,30,10,21].
In several systems such as the retinotectal [10,30], the
retinothalamic [31] and the thalamocortical
[23,24,26,29] ones, ephrinA5 and its receptors have been
found to be expressed in opposite gradients on the pro-
jections and their target respectively, leading to a repul-
sive ligand-receptor interaction. An exception to these
observations was described in the olfactory system,
where high ephrinA5 expressing region is connected by
axons containing an important concentration of
ephrinA5 receptors. This suggests that ephrinA5 inter-
action with its receptors could also mediate an attractive
signal in some systems [17,32].
Although ephrinA5 mRNA expression has been exten-
sively described during development as mentioned
above, distribution of the protein in the developing cen-
tral nervous system is still lacking. Thereby, putative
functions of this molecule during development have
been mainly deduced from its mRNA expression pattern
and from studies using ephrinA5 knock-out mice. How-
ever, the use of these genetic tools may present some
limitations, given that, partial redundancy that exists
between ephrinA-ligands [33,34].
Given the importance of this guidance membrane-
anchored protein location in its actions, sometimes far
from the neurone soma expressing the mRNA, we used
here immunohistochemistry to analyse the spatiotem-
poral ephrinA5 protein expression in the mouse brain
during embryogenesis and in newborns. We compared
the distribution of ephrinA5 protein to the transcript
location, and to previous functional studies, providing
new insights to the involvement of ephrinA5 in the
development of the brain.
Results
To determine the ephrinA5 protein expression, we used
an affinity purified polyclonal antibody directed against
a part of the C-terminal region of the human ephrinA5
protein, described in our previous work [21]. Specificity
of this antibody was checked comparing immunohisto-
chemistry on sagittal sections of E16.5 wild type and
ephrinA5 knock-out (eA5KO) mouse brains. No staining
was detected in the eA5KO brains as shown in figure 1
for the parietal cortex where ephrinA5 wild type expres-
sion is particularly high.
In wild type mice, we identified the presence of
ephrinA5 protein in the mouse brain at four stages dur-
ing embryonic development: E12.5, E14.5, E16.5, E18.5,
and in newborns. Both sagittal and coronal sections
showed dynamic spatiotemporal ephrinA5 immunoreac-
tivity in the telencephalic, diencephalic, mesencephalic
and metencephalic brain structures. Following P0, the
ephrinA5 signal was barely detectable.
Details of ephrinA5 expression distribution are pre-
sented below for each developmental stage, and sum-
marized in table 1.
EphrinA5 protein expression at E12.5
The earliest stage we examined was embryonic day
E12.5 (Figure 2a-l). Within the telencephalon, the olfac-
tory nerve (Figure 2h) presented robust ephrinA5
immunoreactivity. Well-stained cell profiles were also
observed in the neocortex (Figure 2a) and in the piri-
form cortex (Figure 2h). Lateral ganglionic eminence
(Figure 2i) and lateral (Figure 2b) and medial (Figure 2c)
ganglionic eminence differentiating zones exhibited
Figure 1 Anti-ephrinA5 antibody specificity. EphrinA5 protein
expression is represented on sagittal parietal cortex sections of wild
type (wt) and ephrinA5 KO (eA5KO) mice. EphrinA5 was strongly
expressed particularly in the parietal cortex of wild type mice at
E16.5, whereas no staining was observed in the brain of eA5KO
mice. Scale bar: 75 μm. Abbreviations: see list.
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tures, we detected a spatial disparity of ephrinA5
expression in a lateral and ventral (high) to medial and
dorsal (low) gradient (arrowheads in figure 2, panels b
and c respectively).
Among the diencephalic structures, the preoptic differ-
entiating zone (Figure 2d), the preoptic area (Figure 2h),
as well as the hypothalamus and the ventral thalamus,
visualized on coronal (Figure 2e, f) and sagittal sections
(Figure 2j, l), also exhibited strongly labelled ephrinA5
Table 1 EphrinA5 protein distribution in the developing mouse brain
TELENCEPHALON DIENCEPHALON MESENCEPHALON METENCEPHALON
E12.5 ￿ Olfactory nerve
￿ Neocortex
￿ Piriform cortex
￿ LGE
￿ LGE dz l. v.➤m. d.
￿ MGE dz l. v.➤m. d.
￿ Preoptic dz
l. v.➤m. d.
￿ Preoptic area
￿ Ventral thalamus
v. r.➤d. c.
￿ Hypothalamus
v. r.➤d. c.
￿ Mesencephalic
tegmentum
￿ Isthmus
￿ Cerebellum
E14.5 ￿ Olfactory bulb
￿ Neocortex S1 (CP)
￿ Piriform cortex
￿ LGE l. v. r.➤m. d. c.
￿ Subventricular zone
￿ Preoptic area
￿ Ventral thalamus
v. r.➤d. c.
￿ Subthalamic area
￿Hypothalamus
￿ Mesencephalic
tegmentum
￿ Superior colliculus
￿ Inferior colliculus
l.➤m.
￿ Pretectum
l. v.➤m. d.
￿ Commissure of
superior colliculus
￿ Isthmus dz
￿ Cerebellar
vermis
E16.5 ￿ Olfactory structures: GCL, MCL, olfactory tubercle, lateral
olfactory tract
￿ Septum
￿ LGE v. r.➤d. c.
￿ Neocortex (MZ, CP, SP)
￿ Frontal cortex
￿ Parietal cortex (S1)
￿ Insular cortex
￿ Retrosplenial cortex
￿ Piriform cortex
￿ Hippocampus
￿ Preoptic area
￿ Thalamus
v. r.➤d. c.
￿ Hypothalamus
￿ Mesencephalic
tegmentum
￿ Superior colliculus
￿ Inferior colliculus
c.➤r.
￿ Isthmus
￿ Cerebellar
vermis
￿ Pons
E18.5 ￿ Olfactory structures: GCL, olfactory tubercle, lateral olfactory
tract
￿ Striatum
￿ Nucleus accumbens
￿ Septum l. v.➤m. d.
￿ Lateral migratory stream
￿ Piriform cortex
￿ Insular cortex
￿ Cingulate cortex
￿ Retrosplenial cortex
￿ Perirhinal cortex
￿ Neocortex
￿ Parietal cortex (S1)
￿ Occipital cortex (layers I & V)
￿ Hippocampus (CA1, CA3, DG)
￿ Thalamus
l. d.➤m. v.
￿ Hypothalamus
￿ Mesencephalic
tegmentum
￿ Superior colliculus
￿ Inferior colliculus
l.➤m.
￿ Commissure of
superior colliculus
￿ Cerebellum
￿ Pons
P0 ￿ Olfactory structures: GCL, subventricular zone, olfactory
tubercle, lateral olfactory tract
￿ Subventricular zone
￿ Striatum l. v.➤m. d.
￿ Nucleus accumbens
￿ Septum
￿ Parietal cortex
￿ Frontal cortex
￿ Retrosplenial cortex
￿ Thalamus
￿ Hypothalamus
￿ Mesencephalic
tegmentum
￿ Superior colliculus
￿ Inferior colliculus
c.➤r.
￿ Commissure of
superior colliculus
￿ Cerebellum
EphrinA5 was expressed in the same brain regions of the telencephalon, diencephalon, mesencephalon and metencephalon from E12.5, throughout the
embryonic development until P0. The intensity of staining was high from E12.5 to E16.5 and then decreased until P0 to become non-existent in P7 animals (data
not shown). The names of brain regions exhibiting a strong ephrinA5 protein expression were underlined and highlighted in bold, whereas names of brain
structures showing a moderate ephrinA5 protein expression were only underlined. Names of brain regions exhibiting weak or non-existent ephrinA5 protein
expression were not highlighted. Black arrowheads indicate ephrinA5 protein expression gradients. Abbreviations: see list.
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Page 3 of 16immunoreactive cells. We noticed spatial variations of
ephrinA5 expression within the preoptic differentiating
zone, the thalamus and the hypothalamus: in the preop-
tic differentiating zone, ephrinA5 was expressed in a lat-
eral and ventral (high) to medial and dorsal (low)
gradient as shown by arrowhead in figure 2, panel d and
in a ventral and rostral (high) to dorsal and caudal (low)
gradient in the ventral thalamus and in the hypothala-
mus (arrowheads in figure 2, panels j and l respectively).
In the mesencephalon, only the mesencephalic teg-
mentum exhibited a strong level of ephrinA5 immunor-
eactivity (Figure 2k). The ventral mesencephalon was
unstained (Figure 2k).
The metencephalon was moderately stained: ephrinA5
protein was present in the isthmus and in the cerebel-
lum, as visualized in figure 2, panel g.
Overall, at E12.5, ephrinA5 protein was strongly
expressed in the telencephalon, diencephalon,
mesencephalon, whereas its expression was moderate
in the metencephalon (Table 1).
EphrinA5 protein expression at E14.5
At E14.5, ephrinA5 expression was strongly expressed in
the four major regions of the developing brain (Figure
3a-q). In the telencephalon, high level of ephrinA5
immunoreactivity was detected, except in the olfactory
bulb (Figure 3a) and in the subventricular zone
(Figure 3e) where ephrinA5 protein expression was
moderate. Strongly immunoreactive cells were observed
in the neocortex, especially in the cortical plate of the
primitive somatosensory cortex (Figure 3b) and in the
piriform cortex (Figure 3f). EphrinA5 immunoreactivity
was also robust in the lateral ganglionic eminence,
visualized on coronal (Figure 3c, d, f) and sagittal sec-
tions (Figure 3n), in a lateral and ventral (high) to med-
ial and caudal (low) gradient (arrowhead in figure 3,
Figure 2 EphrinA5 protein expression in E12.5 embryonic mouse brain. EphrinA5 protein distribution is represented on coronal sections in
a rostro-caudal sequence (panels a to g), and on sagittal sections in a latero-medial sequence (panels h to l). EphrinA5 protein was strongly
expressed in the telencephalon (panels a, b, c, h, i) diencephalon (panels d, e, f, h, j, l) mesencephalon (panel k) and moderately in the
metencephalon (panel g). Arrowheads in panel b, c and d indicate a lateral and ventral (high) to medial and dorsal (low) gradient in the lateral
and medial ganglionic eminence, and preoptic differentiating zones respectively. In panel j and l, arrowheads show a ventral and rostral (high) to
a dorsal and caudal (low) gradient of ephrinA5 protein in the ventral thalamus and hypothalamus respectively. Scale bar: panels a, c: 75 μm;
panel b: 250 μm; panel d: 150 μm; panels e, f, g, h, i, l: 300 μm; panel j: 350 μm; panel k: 200 μm. Abbreviations: see list.
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caudal (low) gradient (arrowhead in figure 3, panel n).
In the diencephalon, ephrinA5 was strongly expressed
in the preoptic area (Figure 3n) and in the ventral thala-
mus, visualized on coronal (Figure 3d) and on sagittal
sections in a ventral and rostral (high) to dorsal
and caudal (low) gradient (Figure 3n). We also observed
a high ephrinA5 staining in the subthalamic area
(Figure 3i) and moderate immunoreactivity in the
hypothalamus (Figure 3q).
In the mesencephalon, coronal (Figure 3j) and sagittal
(Figure 3o) sections in the mesencephalic tegmentum
exhibited robust ephrinA5 immunoreactivity. Further-
more, ephrinA5 was strongly expressed in the inferior
Figure 3 EphrinA5 protein expression in E14.5 embryonic mouse brain. EphrinA5 protein distribution is represented on coronal sections in
a rostro-caudal sequence (panels a to m) and on sagittal sections in a latero-medial sequence (panels n to q). EphrinA5 protein was differentially
expressed within brain regions. EphrinA5 was strongly expressed in the telencephalon (panels b, c, d, f, n) in the diencephalon (panels d, i, n) in
the mesencephalon (panels g, j, k, o) and in the metencephalon (panels l and p) excepted in the olfactory bulb (panel a), the subventricular
zone (panel e), the hypothalamus (panel q) and the isthmus differentiating zone (panel l) where expression was moderate. Arrowheads in panels
c and g indicate ephrinA5 expression gradients respectively in the lateral ganglionic eminence and in the pretectum, in a lateral and ventral
(high) to medial and dorsal (low) direction. The inferior colliculus exhibited a lateral (high) to medial (low) gradient (arrowhead in panel k).
Arrowheads in panel n show ventral and rostral (high) to dorsal and caudal (low) gradients in the lateral ganglionic eminence and the ventral
thalamus. Scale bar: panels a, b, i, j, k, q: 150 μm; panel c: 300 μm; panel d: 400 μm; panels e, h, m: 75 μm; panels f, g, l, p: 200 μm; panel n: 350 μm;
panel o: 250 μm. Abbreviations: see list.
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Page 5 of 16and superior colliculi (Figure 3k) and in the pretectum
(Figure 3g). We observed a lateral and ventral (high) to
medial and dorsal (low) gradient in the pretectum
(arrowhead in figure 3, panel g) and a lateral (high) to
medial (low) gradient in the inferior colliculus (arrow-
head in figure 3, panel k). The commissure of superior
colliculus (Figure 3g, k) also presented robust ephrinA5
immunoreactivity. In return, the ventral mesencephalon
was unstained (Figure 3o).
In the metencephalon, cells from the isthmus differen-
tiating zone were weakly stained (Figure 3l), whereas the
cerebellar vermis exhibited a strong ephrinA5 expression
(Figure 3p).
Finally, we noticed that cells from the neuroepithelia
of the third (Figure 3h, i) and fourth (Figure 3m) ventri-
cles and of the aqueduct (Figure 3o) exhibited strong
ephrinA5 immunoreactivity.
Overall, ephrinA5 protein was strongly expressed in
the same brain regions than earlier in the development.
The olfactory bulb, the subventricular zone, the
hypothalamus and the isthmus differentiating zone were
however moderately stained (Table 1).
EphrinA5 protein expression at E16.5
At E16.5, the intensity of ephrinA5 immunostaining was
high in most of the developing brain structures (Figure
4a-u). The telencephalon exhibited strong ephrinA5
expression in olfactory structures such as the granule
(Figure 4a) and the mitral (Figure 4b) cell layers of the
olfactory bulb, the olfactory tubercle (Figure 4e) and the
lateral olfactory tract (Figure 4h). We also detected a
high level of ephrinA5 immunoreactivity in the septum
(Figure 4s) and in the lateral ganglionic eminence, as
visualized on coronal (Figure 4d, e) and sagittal sections
(Figure 4u). Within the lateral ganglionic eminence,
ephrinA5 was expressed in a ventral and rostral (high)
to dorsal and caudal (low) gradient (arrowheads in fig-
ure 4, panels e and u). Moreover, the frontal (Figure 4b)
and parietal (Figure 4d) parts of the neocortex exhibited
a strong ephrinA5 protein expression in the marginal
zone, the cortical plate and the subplate as observed in
the primitive somatosensory cortex (Figure 4c). Insular
(Figure 4d), retrosplenial (Figure 4f) and piriform (Fig-
ure 4h) cortices also exhibited ephrinA5 immunoreac-
tive cells, although these two latter structures showed
less intense immunostaining. EphrinA5 protein expres-
sion was moderate in the hippocampus (Figure 4j).
In the diencephalon, ephrinA5 staining in the preoptic
area (Figure 4l) was moderate compared to previous
stages, whereas the thalamus, visualized on coronal
(Figure 4g, i, j) and sagittal sections (Figure 4u), still
exhibited strong ephrinA5 expression. In this structure,
ephrinA5 staining was higher in the ventral and rostral
part than in the dorsal and caudal part (arrowheads in
figure 4, panels i and u). An intense staining was also
detected in the hypothalamus (Figure 4o).
In the mesencephalon, the mesencephalic tegmentum
(Figure 4m) and the superior colliculus (Figure 4n)
exhibited strongly immunostained cells. EphrinA5 label-
ing was also detected in the ventricular zone of the
inferior colliculus in a caudal (high) to rostral (low) gra-
dient (arrowhead in figure 4, panel t). The ventral
mesencephalon was unstained (Figure 4m).
In the metencephalon, the isthmus was moderately
stained (Figure 4p) whereas high immunoreactivity in
the cerebellum (Figure 4r) and in the pons (Figure 4p)
was detected.
Neuroepithelia of the third (Figure 4k) and fourth
(Figure 4p, q) ventricles and neuroepithelium of the
aqueduct (Figure 4m, n) exhibited ephrinA5 immunos-
taining as well.
Moreover, to specify retinocollicular mapping, we
tested the expression of ephrinA5 protein in the retina.
Immunohistochemistry localized ephrinA5 protein in
the nasal part of the retina and the retinal ganglion cell
layer (Figure 5).
Overall, E16.5 embryonic stage showed high levels of
ephrinA5 immunoreactivity in the same regions than those
previously described earlier in the development, with the
exception of the preoptic area that was moderately stained
compared to E12.5 and E14.5 stages (Table 1).
EphrinA5 protein expression at E18.5
At E18.5, ephrinA5 protein expression was generally less
intense than earlier in the development (Figure 6a-v). In
the telencephalon, the granule cell layer of the olfactory
bulb (Figure 6a), the olfactory tubercle and the lateral
olfactory tract (Figure 6b) exhibited a moderate immu-
noreactive intensity. Moreover, ephrinA5 expression was
weak in the striatum as shown on coronal (Figure 6d, h)
and sagittal sections (Figure 6v), and almost non-exis-
tent in the nucleus accumbens (Figure 6v). A moderate
ephrinA5 expression was detected in the septum in a
lateral and ventral (high) to medial and dorsal (low) gra-
dient (arrowhead in figure 6, panel f) and in the lateral
migratory stream (Figure 6d). The piriform (Figure 6b),
insular (Figure 6d, h), cingulate (Figure 6c), including
the retrosplenial cortex (Figu r e6 i ) ,a n dt h ef r o n t a lc o r -
tex (Figure 6e) exhibited weak staining intensity. Moder-
ate intensity of ephrinA5 expression was observed in the
perirhinal cortex (Figure 6n), in layers I and V in the
occipital cortex (Figure 6m) and in the primary somato-
sensory region of the parietal cortex (Figure 6g). In the
hippocampus, weak immunostaining was localized in
the CA1 and CA3 regions, and in the dentate gyrus
(Figure 6l).
In diencephalic structures, ephrinA5 expression was
moderate in the thalamus, with the strongest
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Page 6 of 16Figure 4 EphrinA5 protein expression in E16.5 embryonic mouse brain. EphrinA5 protein distribution is represented on coronal sections in
a rostro-caudal sequence (panels a to r) and on sagittal sections in a medio-lateral sequence (panels s to u). At 16.5, ephrinA5 protein was
strongly expressed in the telencephalon (panels a, b, c, d, e, j, s, u) diencephalon (panels g, i, j, l, o, u) mesencephalon (panels m, n, t) and
metencephalon (panels r, p) excepted in the retrosplenial (panel f) and piriform (panel h) cortices, in the hippocampus (panel j) in the preoptic
area (panel l) and in the isthmus (panel p) where the expression was moderate. In the lateral ganglionic eminence, ephrinA5 protein was
expressed in a ventral and rostral (high) to dorsal and caudal (low) gradient (arrowheads in panels e and u). In panel i and u, arrowheads
represent a ventral and rostral (high) to dorsal and caudal (low) gradient in the thalamus and in panel t, a caudal (high) to rostral (low) gradient
in the inferior colliculus. Scale bar: panels a, k, q: 75 μm; panels b, d, n: 350 μm: panels c, e, o, r: 200 μm; panels f, l, t: 150 μm; panels g, h, i, j, p: 300
μm; panels m, u: 400 μm. Abbreviations: see list.
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vious stages, thus leading to a lateral and dorsal (high)
to medial and ventral (low) gradient (arrowhead in fig-
ure 6, panel j). Weakly stained cells were detected in the
hypothalamus (Figure 6p).
In the mesencephalon, the commissure of the superior
colliculus (Figure 6o), the mesencephalic tegmentum
(Figure 6q) and the superior and inferior colliculi
(Figure 6r) exhibited ephrinA5 immunoreactive cells.
EphrinA5 expression was however stronger in the infer-
ior part of the colliculus than in the superior region,
exhibiting a lateral (high) to medial (low) gradient
(arrowhead in figure 6, panel r). The ventral mesence-
phalon was unstained (Figure 6q).
In the metencephalon, the cerebellum and the pons
were weakly stained (Figure 6t).
Finally, cells from the neuroepithelia of the third
(Figure 6k, p) and fourth (Figure 6u) ventricles, and the
neuroepithelium of the aqueduct (Figure 6q, r, s) exhib-
ited high immunoreactivity.
EphrinA5 protein expression at P0
In newborn mice, ephrinA5 expression intensity was
dramatically decreased in all regions of the brain, com-
pared to the previous stage E18.5 (Figure 7a-q). In the
telencephalon, we were however able to detect weakly
stained cells in the olfactory structures: the granule cell
layer (Figure 7a), the olfactory subventricular zone (Fig-
ure 7b), the olfactory tubercle (Figure 7f), and the lateral
olfactory tract (Figure 7f). Moreover, ephrinA5 immu-
noreactive cells were observed in the subventricular
zone (Figure 7d), in the striatum (Figure 7e, l), and in
the nucleus accumbens (Figure 7f). In the striatum, we
detected a discrete ephrinA5 expression gradient from
the lateral and ventral (high) to the medial and dorsal
(low) parts (arrowhead in figure 7, panel e). Moderate
ephrinA5 staining was observed in the septum (Figure
7o) whereas the parietal (Figure 7e, h), the frontal (Fig-
ure 7c) and the retrosplenial (Figure 7g) cortices exhib-
ited weak ephrinA5 protein expression. The
hippocampus (Figure 7h), the piriform, the occipital and
the perirhinal cortices were unstained (data not shown).
Within the diencephalic structures, a very weak
ephrinA5 signal was present in the dorsal and in the
ventral part of the thalamus (Figure 7i, l). The hypotha-
lamus expressed moderate ephrinA5 protein expression
level (Figure 7p).
In the mesencephalon, the mesencephalic tegmentum
(Figure 7q) exhibited weakly immunostained cells as
well as the superior (Figure 7j) and inferior (Figure 7m)
colliculi. In the inferior colliculus, we however detected
a caudal (high) to rostral (low) gradient (arrowhead in
figure 7, panel m). The commissure of superior collicu-
lus exhibited moderate ephrinA5 immunoreactivity
(Figure 7k).
Within the metencephalon, weak ephrinA5 immunor-
eactivity was detected in the cerebellum (Figure 7n).
Ventricles and Sylvius aqueduct’s neuroepithelia were
unstained (data not shown).
Overall, at P0, ephrinA5 protein expression decreased
in all brain regions compared to previous stages. The
strongest ephrinA5 protein expression was found in the
septum, in the hypothalamus and in the commissure of
superior colliculus, although these protein expression
levels were still moderate compared to the earliest
developmental stages (Table 1).
Following P0, ephrinA5 expression was barely
detectable.
Discussion
The present work describes for the first time, the distri-
bution of ephrinA5 protein in the embryonic developing
mouse brain. EphrinA5 protein expression appeared to
be dynamic and complex, and particularly high from
E12.5 to E16.5 in the olfactory bulb, the cortex, the
LGE/striatum, the thalamus, and the colliculus. Its
expression generally decreased from E18.5 to become
very weak at P0 and extinct at P7 (data not shown),
contrary to the mRNA level that stays elevated in the
newborn [9]. In spite of this graded decrease, ephrinA5
protein expression at P0 was still observed in the same
regions of the brain than at earlier stages (i.e. in the
olfactory structures, cortex, striatum, thalamus, hypotha-
lamus, nucleus accumbens, colliculus and cerebellum).
As primary molecular events in topographic map forma-
tion occur between E15 and P7 in the mouse [49], this
suggests that high ephrinA5 expression during
Figure 5 EphrinA5 protein expression in E16.5 embryonic
mouse retina. EphrinA5 protein distribution is represented on
horizontal section of mouse retina. EphrinA5 is expressed in the
nasal part of the retina and retinal ganglion cells. Scale bar: 130 μm.
Abbreviations: see list.
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Page 8 of 16Figure 6 EphrinA5 protein expression in E18.5 embryonic mouse brain. EphrinA5 protein distribution is represented on coronal sections in
a rostro-caudal sequence (panels a to u) and on a sagittal section (panel v). At E18.5, ephrinA5 is mostly expressed in the telencephalon
especially in olfactory structures (panels a, b) in the septum (panel f) in the lateral migratory stream (panel d) and in the cortex (panels g, m, n,
v) at a moderate level. The thalamus (panel j) and inferior colliculus (panel r) showed also a moderate expression, whereas other brain structures
exhibited weak ephrinA5 immunoreactivity. Arrowheads in panels f, j and r represent respectively a lateral and ventral (high) to medial and
dorsal (low) gradient in the septum, a lateral and dorsal (high) to medial and ventral (low) gradient in the thalamus and a lateral (high) to
medial (low) gradient in the inferior colliculus. Dotted line in panel r indicates the limit between the superior and the inferior colliculi. Scale bar:
panels a, b: 250 μm; panels c, e, n: 400 μm; panels d, j, r, t: 300 μm; panels f, g, l: 200 μm; panel h: 450 μm; panels i, m: 250 μm; panel k: 100 μm;
panel o: 110 μm; panel p: 175 μm; panel q: 150 μm; panel s: 100 μm, panel v: 550 μm. Abbreviations: see list.
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Page 9 of 16Figure 7 EphrinA5 protein expression in newborn mouse brain. EphrinA5 protein distribution is represented on coronal sections in a rostro-
caudal sequence (panels a to k) and on sagittal sections in a medio-lateral sequence (panels l to q). EphrinA5 protein expression dramatically
decreased in all brain regions compared to previous stages. The strongest expression was observed in the septum (panel o) the hypothalamus
(panel p) and in the commissure of superior colliculus (panel k). Arrowheads in panels e and m indicate respectively a discrete lateral and ventral
(high) to medial and dorsal (low) gradient in the striatum and a caudal (high) to rostral (low) gradient in the inferior colliculus. Scale bar: panel a:
250 μm; panels b, m, p, q: 200 μm; panels c, e, f, g, h, n: 300 μm; panels d, k: 150 μm; panels i, l: 500 μm; panel j: 400 μm; panel o: 350 μm.
Abbreviations: see list.
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Page 10 of 16embryogenesis, may participate in early target connec-
tion mechanisms, whereas ephrinA5 may be implicated
to a lesser extent in map remodelling process during the
first postnatal week. This transient expression during
embryonic development is in line with early axon gui-
dance and topographic mapping in the olfactory, the
retinotectal, the thalamocortical, the corticothalamic and
the mesostriatal systems. This indicates multiple func-
tions of this molecule in the establishment of these sys-
tems, as discussed in the following sections.
Central olfactory system
To the best of our knowledge, the olfactory system is
the only brain system, in which ephrinA5 expression has
been studied at the protein level, using immunohisto-
chemistry [35]. Our study is complementary to this one
as it brings new data especially concerning the expres-
sion of the protein in the secondary olfactory neuron
population.
Olfaction initiates in the nasal neuroepithelium where
primary olfactory neurons reside, each one encoding a
single odour receptor type [36,37]. These neurons send
axons, forming the olfactory nerve and project to the
olfactory bulb in the rostro-ventral telencephalon, where
they sort out and target specific glomeruli. Glomeruli are
designed as contact zone between growth cones of the
primary olfactory neurons and dendrites of secondary
olfactory neurons, known as mitral and tufted cells
located in the olfactory bulb [35]. Primary olfactory neu-
rons, mitral and tufted cells are neurons supporting early
synaptic relays of the mouse olfactory system and so arise
in a relatively parallel fashion between E9.5 and E10.5
[38]. In our study, we showed for the first time that the
olfactory nerve expressed ephrinA5 in early embryogen-
esis (E12.5), suggesting either an involvement of this
molecule in the guidance of primary olfactory neurons
into the olfactory bulb or, an implication of ephrinA5 in
the fasciculation of primary olfactory axons inside the
olfactory nerve, possibly through an interaction with
EphA4- and/or EphA5-receptors, shown to be expressed
during embryogenesis in the olfactory nerve [35].
Interestingly, we found that ephrinA5 was expressed
in the mitral cell layer of the olfactory bulb, transiently
during embryogenesis, at E16.5. The function of this
molecule at this precise stage is still unclear but it may
be implicated in the positioning of the mitral cell layer
in the olfactory bulb. Indeed, ephrins are known to be
involved in cell migration and boundary formation in
other nervous systems [2,3], and at this stage the cell
body of developing mitral cells appears to transform
from tangential to radial orientation with rearrangement
of its microtubules structure [39]. Moreover, the pre-
sence of potential ephrinA5 receptors such as EphA3
[40], EphB2 [41], EphA5 [35,42,43], EphA7 and EphA4
[35] has been also described in the mitral cells during
embryogenesis. This suggests that ephrinA5 and its
receptors are not expressed in complementary gradient
as it has been described for other systems such as the
retinotectal one [8,44]. Instead, we showed that
ephrinA5 is uniformly expressed in this structure as for
its receptors [40-42,35,20]. This ligand-receptor interac-
tion may result in an attraction of the cells, thus regu-
lating the connections of mitral cells. Indeed, this
mechanism has already been demonstrated in the acces-
sory olfactory system, where axons expressing high
levels of ephrinA5 project to regions of the accessory
olfactory bulb that express high levels of EphA6, sug-
gesting that EphA6-ephrinA5 interaction promotes
adhesion or attraction between first and second order
accessory neurones [17].
Later during embryogenesis, the mitral cells leave the
olfactory bulb in the lateral olfactory tract, which
synapses on five major regions of the mature telence-
phalon including the olfactory tubercle and the piriform
cortex that project to the thalamus. We detected the
expression of ephrinA5 protein from E16.5 on in the lat-
eral olfactory tract and the olfactory tubercle. This
expression was strong at E16.5, slightly diminished at
E18.5 and became very weak at P0, suggesting that this
molecule may be involved in the secondary olfactory
neuron guidance, since its presence is concomitant to
the development of this telencephalic pathway [45].
EphrinA5 expression in the lateral olfactory tract and
olfactory tubercle may also have a role in the fascicula-
tion of axons inside these structures, since fasciculation
can be regulated by manipulating chemorepulsive inter-
actions mediated by Eph receptors [46]. As axon path-
finding in olfactory map formation has been mainly
investigated when primary olfactory axons enter the
olfactory bulb glomeruli [47], our data give new insights
concerning the guidance of the secondary mitral cell
axons onto the thalamus.
Finally, we detected the presence of ephrinA5 protein
in the piriform cortex at E12.5, earlier than the expres-
sion of this protein in the mitral cells and in the lateral
olfactory tract that appeared at E16.5. This ephrinA5
expression in the piriform cortex dramatically decreased
from E18.5, when the secondary olfactory axons connect
this target [45]. This suggests that ephrinA5 protein
expression in the piriform cortex during early embryo-
genesis may not be related to the connection of the
axons of the lateral olfactory tract, but rather may play a
role in the formation of the piriform cortex architecture.
Visual system
Expression of ephrinA5 transcript has been extensively
studied in this system and especially in the retinocollicu-
lar topographic mapping [10,48-50]. We investigated
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Page 11 of 16ephrinA5 protein expression in the retina and detected a
high expression in the nasal part compared to the tem-
poral one. This result is in accordance with the pre-
viously described retinal ephrinA5 expression pattern in
the chick [51] and with ephrinA5 mRNA expression
found in a high-nasal-to-low-temporal gradient in the
developing mouse embryo retina [52]. As previously
described, the mouse retinal ganglion cells also
expressed EphA5 and EphA6 receptors [53]. This sug-
gests that ephrinA5 protein may be co-expressed with
these molecules and interact in cis or in trans then
modulating the tectum or colliculus connectivity.
Indeed, several studies confirmed the role of axonally
expressed ephrinA ligands in the development of the
retinotectal projection [54]. However, whether growth
cones switch between cis and trans configuration or cis
and trans configurations occur in parallel in the same
growth cone, is still unclear.
As our findings in the retina, the results of our analy-
sis in the central visual system were generally consistent
with the findings of the past surveys describing the
mRNA distribution of ephrinA5 in the 3 main targets of
retinal ganglion cell axons: the thalamus, the pretectum,
and the superior colliculus. Indeed, we showed that
ephrinA5 protein is strongly expressed in these struc-
tures especially from E14.5 to E16.5 (Table 1), when the
axons of the optic tracts reach their final destinations in
the superior colliculus at E14 [30], and in the thalamic
dorsal lateral geniculate nuclei at E16 [10]. This is in
accordance with an implication of ephrinA5 in the topo-
graphic mapping of the visual connections especially in
the superior colliculus [48-50]. It has to be noticed how-
ever, that ephrinA5 mRNA expression was described as
soon as E12.5 in the developing superior colliculus
[28,30], whereas we did not detect ephrinA5 protein in
this structure earlier than E14.5. This suggests that
ephrinA5 may be implicated in this topographic map-
ping only from E14.5, when the retinal connections
reach the superior colliculus. On the contrary, in the
thalamus and in the mesencephalic tegmentum,
ephrinA5 protein level was elevated from E12.5
onwards. This expression seems to be too precocious to
involve ephrinA5 in visual connection mapping and
more probably may be implicated in the formation of
other systems involving the thalamus, such as the thala-
mocortical system as discussed below, and the mesence-
phalic tegmentum, such as the rubrospinal system.
The general high ephrinA5 expression during embryo-
g e n e s i s ,m a yh i g h l i g h tar o l ef o re p h r i n A 5i nt h ei n i t i a l
diffuse projection when retinal ganglion cells substan-
tially overshoot their appropriate target by E16 along
the antero-posterior axis of the superior colliculus [48]
and at a lesser extent later on, when map remodelling
occur during the first postnatal week.
EphrinA5 RNA is known to be expressed in a caudal
(high) to rostral (low) gradient in the mouse superior
colliculus [44,50,55]. This gradient is thought to be at
the basis of the chemorepellent action of ephrinA5 on
retinal ganglion cell’s axons arising from the nasal part
of the retina [50]. However, at the protein level,
ephrinA5 expression was homogenous in the superior
colliculus without any detectable expression gradient. As
suggested by Greferath et al. [56] concerning EphA4
receptor expression in the striatum, this may be due to
the fact that the antibody localizes ephrinA5 protein in
both cell bodies and axons bundles, whereas RNAs are
concentrated in the cell somas. Moreover, studies
describing the EphA5 protein expression in the develop-
ing mouse [43] did not detect any protein gradient
expression.
Among studies exploring the expression of EphA-
receptors at the protein level in the developing mouse
brain, some showed that the potential ephrinA5 recep-
tors EphA4 and EphA5, are expressed in the central
visual system: EphA4 protein is present in the thalamus
and superior colliculus from E11 to P6; and in the pre-
tectal nucleus from E15 to P6 [56]. EphA5 protein is
expressed in the geniculate nucleus of the thalamus
from E17 as well as in the pretectum and the superior
colliculus from E9 to E17 [43]. Together with our pre-
sent work, these findings suggest a concomitant expres-
sion of ephrinA5 with (1) EphA4 and EphA5 in the
superior colliculus, (2) EphA4 in the thalamus and (3)
EphA5 in the pretectum. Moreover, a detailed analysis
of protein gradients inside these regions may help to
understand their interactions and their chemorepulsive
or chemoattractive actions. However, it is unlikely that
the co-expression of ligand and receptor in the same
region of the visual system is responsible of an attractive
mechanism, since it has been extensively shown, using
in vitro studies and double ephrinA2/ephrinA5 knock-
out mice [30,48-50], that the topographic map of the
visual system is established by a chemorepellent activity
of ephrinAs [50]. Nevertheless, it may be that ligands
and receptors are present on the same cells, as it has
been shown in the chick retinal ganglion cells, where
ephrinA2, ephrinA5 and EphA5 mRNA are co-expressed
[51]. In this case, the presence of ephrinA-ligand on the
retinal ganglion cells could control the EphA-receptor
function through a modulation of its intracellular signal-
ling pathway [51] as discussed above.
Cortex and thalamocortical projections
We detected ephrinA5 protein in the developing cortex
from E12.5 to E18.5 with an expression pattern becoming
more complex as cortical layers were forming. We found
a particularly strong signal at E16.5 in the primitive pri-
mary somatosensory cortex (S1), when thalamic axons
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Page 12 of 16reach the subplate zone. This is consistent with the pre-
sence of ephrinA5 mRNA in the subplate and cortical
plate of S1 at this stage [22-24,27]. Indeed, ephrinA5 is
thought to interact with and repulse ventrobasal thalamic
terminal arbors expressing EphA4, and to be responsible
for the precise topographic mapping of thalamic afferents
into S1 [24]. Moreover, we showed a strong ephrinA5
protein expression in other regions of the developing cor-
tex, especially in the parietal, frontal and insular cortices
at E16.5, suggesting that ephrinA5 may be involved in
the refinement of other thalamocortical projections and
probably through an interaction with 3 potential recep-
tors: EphA3, EphA4 and/or EphA5 that have been
detected in these regions during mouse embryogenesis.
Indeed, EphA3 protein is expressed in the cortical plate
and cortical intermediate zone from E12 to P0, especially
in thalamocortical axons [40]. EphA4 protein is
expressed from E11 to P6 in the developing cortex [56],
and EphA5 protein is present in the intermediate zone
and cortical plate [43] whereas its transcript is expressed
in the dorsal and medial thalamus that connect to the
developing cortex [57], suggesting an expression of
EphA5 protein in the thalamocortical projections.
Thalamus and corticothalamic projections
Previous studies showed different patternso fe p h r i n A 5
mRNA expression, depending of the thalamic nuclei and
the stage observed: at E13.5, Bolz et al. [27] described a
weak mRNA expression in the ventricular zone of the
dorsal thalamus at the caudal level with no detectable
expression in the mid- or rostral levels of the dorsal tha-
lamus. Feldheim et al. [10] described ephrinA5 mRNA
expression from E14.5, in the dorsal and ventral lateral
geniculate nuclei in a ventral, lateral and anterior (high)
to dorsal, medial and posterior (low) gradient. Between
E16.5 and E18.5, nuclei of the lateral part of the dorsal
thalamus [27] and ventral nuclei [29] both exhibit
ephrinA5 mRNA. Our results partially match with these
previous studies, as we showed here that ephrinA5 pro-
tein was strongly expressed in the thalamus in a ventral
and rostral (high) to dorsal and caudal (low) gradient
especially from E12.5 to E16.5. Interestingly, we
observed that this gradient inverted from E16.5, when
cortical axons connect the thalamus [58]. This is consis-
tent with an implication of ephrinA5 in the corticothala-
mic projection establishment as proposed by Torii and
Levitt [59] who hypothesized that the corticothalamic
projections are directed by ephrinA-EphA signalling and
more precisely that axons from sensory cortex find a
precise target in the thalamus by responding to local
levels of ephrinA5. In this region, ephrinA5 may interact
with EphA4 protein, described in the thalamus from
E13.5 to postnatal stages [56] to ensure the formation of
terminal corticothalamic arbors.
Mesostriatal system
EphrinA5 protein was strongly expressed in the main
target structure of the ventral mesencephalic axons: the
lateral ganglionic eminence and later in development,
the striatum. As described for mRNA levels [19,21], this
expression was high from E12.5 to E16.5 and then
diminished later in development. We observed a gradu-
ated ephrinA5 protein expression in a ventral and ros-
tral (high) to a dorsal and caudal (low) gradient that was
not spatially concordant with the ephrinA5 RNA expres-
sion, described as not graded in developing striatum
[60,19,21]. As we discussed in a previous work, it is
likely that the presence of this ephrinA5 protein expres-
sion gradient helps mesencephalic neuron subpopula-
tions to differentially connect the dorsal and ventral
parts of the striatum during development [21].
No ephrinA5 protein was detected in the ventral
mesencephalon from E12.5 to P0, suggesting that this
protein was present exclusively at the target site of the
mesotriatal projections, when the mesencephalic axons
reach the LGE [61]. This strongly suggests that
ephrinA5 may be involved in the refinement of mesen-
cephalic arbors in the striatum especially by interacting
with EphA5, expressed in the LGE between E13 and
E17 [43] and in the ventral mesencephalon in the dopa-
minergic mesencephalic cells projecting to the LGE [21].
Finally, the implication of ephrinA5 in the mesencepha-
lic projections onto the striatum is in accordance with
previous work showing that disruption of EphA/ephrinA
interactions resulted in the mistargeting of a fraction of
mesencephalic dopaminergic projections [62].
Conclusions
I nt h ep r e s e n ts t u d yw ep r o v i d et h ef i r s td e t a i l e d
description of ephrinA5 protein distribution in the
embryonic developing mouse brain. We found that
ephrinA5 is strongly expressed from E12.5 to E16.5, in
the olfactory bulb, the cortex, the striatum, the thala-
mus, and the colliculi, suggesting its implication in
topographic mapping of olfactory, retinotectal, thalamo-
cortical, corticothalamic and mesostriatal systems. These
new data may help to characterise the molecular basis
of pathfinding of these systems, during development.
Moreover, given the importance of developmental pro-
cesses in brain repair, these results may open new tracks
in the improvement of pathway restoration following
cell transplantation in the damaged brain.
Methods
Animals
Housing of the animals and all animal experimental pro-
cedures were carried out in accordance with the guide-
lines of the French Agriculture and Forestry Ministry
(decree 87849) and the European Communities Council
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the number of animals used and their suffering.
Embryonic and postnatal C57Bl/6 wild type mice of
different developmental stages (E12.5, E14.5, E16.5,
E18.5, P0) were used in this study. E0.5 was defined as
the plug date, and P0 as the date of birth. Moreover,
E16.5 embryonic eA5KO mice were used to test the
anti-ephrinA5 antibody specificity. These mice were
kindly provided by Dr. P. Vanderhaeghen (Belgium).
Genotyping of eA5KO mice
Mice genomic DNA was extracted from 5 mm-long tail
fragments. The tissue was digested in an alkaline lysis
solution (25 mM NaOH, 0.2 mM Na2-EDTA, pH = 12) at
94°C for 1 h. The lysate containing the genomic DNA was
then neutralized by the addition of 40 mM Tris-HCl, pH5.
Amplification was performed using the PCR Accu-
Prime Taq DNA Polymerase System (Invitrogen)
according to the protocol provided by the manufacturer.
Sense primer for ephrin-A5 is 5′-TCC AGC TGT GCA
GTT CTC CAA AAC A-3′. Antisense primers for the
detection of ephrin-A5 wild type and mutant alleles are
respectively 5′-ATT CCA AGA GGG GTG ACT ACC
ACA TT-3′ and 5′-AGC CCA GAA AGC GAA GGA
GCA AAG C-3′. They were designed to generate PCR
fragments of 397 and 513 bp respectively. After an
initial step of DNA denaturation at 94°C for 5 min,
amplification was carried out for 30 cycles at 94°C for 1
min, 46.5°C for 1 min and 72°C for 1 min. A final step
of 5 min at 72°C was performed.
After separation by electrophoresis on 2% agarose gels,
the size of the PCR products obtained allowed us to dis-
tinguish between the wild-type ephrin-A5(+/+) animals
(one PCR product at 397 bp) from mutated animals,
homozygous ephrin-A5 (-/-) (one PCR product at 513
bp) and heterozygous ephrin-A5 (+/-) (two PCR pro-
ducts at 397 and 513 bp).
Antibodies
Primary antibody directed against the C-terminal
domain of ephrinA5 has been reported before [21]. This
is a polyclonal goat anti-ephrinA5 antibody (sc-6075,
Santa Cruz Biotechnology, Santa Cruz, USA) that recog-
nizes a 19 amino acid epitope that falls in the last
50 amino acids of the human ephrinA5 protein. This
antibody was used at a dilution of 1:100. Secondary bio-
tinylated rabbit anti-goat antibody was purchased from
Vector (Burlingame, CA) and used at a dilution of 1:200.
Specificity of this antibody was checked comparing
immunohistochemistry in wild type and homozygous
ephrinA5KO mice.
Immunohistochemistry
Pregnant wild type and eA5KO mice were cervically dis-
located at different developmental stages. Embryonic
(E12.5, E14.5, E16.5, E18.5) and newborn (P0) wild type
brains were dissected out and E16.5 wild type embryo
heads containing the eyes were taken. Homozygous
E16.5 eA5KO embryo brains were taken to check the
specificity of the anti-ephrinA5 antibody. These tissues
were fixed in 4% PFA overnight and cryoprotected with
30% sucrose in 0.1 M phosphate buffered saline (PBS)
for 48 h at 4°C, excepted for the E16.5 embryo heads
that were dehydrated in alcool and butanol after fixa-
tion. Two brains of each developmental stage were then
frozen in cold isopentane and cut on a cryostat into
sagittal and coronal 20 μm-thick sections. Sections were
stored at -80°C until immunohistochemistry processing.
Dehydratation of heads, consisting of successive baths of
twice 1 hr each in 70°, 95°, 100°alcool, butanol and buta-
nol/paraffin (v/v), were embedded in paraffin and cut on
a microtome into horizontal 10 μm-thick sections.
Before immunohistochemistry, paraffin sections were
deparaffinized in toluene solution three time for 5 min
and rehydrated twice in successive alcool baths of 100°,
90°, 70°, 30°and distilled water for 5 min each.
Immunohistochemistry was performed as previously
described in Deschamps et al,[ 2 1 ] .B r i e f l y ,t h es e c t i o n s
were rehydrated in 0.1 M potassium phosphate buffered
saline (KPBS) (0.9% NaCl, 0.08 M K2HPO4, 0.02 M
KH2PO4), and then post-fixed with 4% PFA for 2 h at
room temperature (RT). After several washes with 0.1
M KPBS, sections were incubated with a blocking solu-
tion (5% rabbit serum, 0.25% Triton-X100 in 0.1 M
KPBS) for 3 h at RT to saturate non-specific sites. The
anti-ephrinA5 antibody was then applied on sections
overnight at 4°C. After several washes with 0.1 M KPBS,
the sections were incubated with the secondary biotiny-
lated antibody for 1 h 30 at RT. After extensive washing
with 0.1 M KPBS, ephrinA5 expression was visualized
with neutravidin™ fluorescein conjugate (Molecular
Probes, Eugene, USA), diluted at 1/200 in blocking solu-
tion, for 45 min at RT. Following several washes with
0.1 M KPBS, slides were covered with mowiol anti-fade
mounting medium [63,64].
Immunostaining analysis
Sections were observed and photographed with a micro-
scope (Olympus BX60F5) and camera setting (SPOT32,
Diagnostic instruments, inc). Image brightness and con-
trast were adjusted with Adobe Photoshop in the same
conditions for all pictures. Brain structures were identi-
fied using brain mouse atlases [65,66].
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Am: amygdala; Aq: Sylvius acqueduct; Aq ne: Sylvius acqueduct
neuroepithelium; Bst: bed nucleus of stria terminalis; c: caudal; CA1, 3:
hippocampal area CA1, 3 (Ammon’s Horn); CB: cerebellum; CBv: cerebellar
vermis; Cc: cingulate cortex; CP: cortical plate; d: dorsal; DG: dentate gyrus;
dThal: dorsal thalamus; ec: external capsule; eA5KO: ephrinA5 knock-out; fn:
fastigial nucleus; Fr: frontal cortex; GCL: granule cell layer; H: hippocampus;
Hypothal: hypothalamus; IC: inferior colliculus; In: insular cortex; IS: isthmus;
isdz: isthmus differentiating zone; KPBS: potassium phosphate buffered saline
l: lateral; LGE: lateral ganglionic eminence; LGE dz: lateral ganglionic
eminence differentiating zone; lms: lateral migratory stream; lot: lateral
olfactory tract; LV: lateral ventricle; m: medial; MCL: mitral cell layer; MeT:
mesencephalic tegmentum; MGE: medial ganglionic eminence; MGE dz:
medial ganglionic differentiating zone; MZ: marginal zone; n: nasal; nAcb:
nucleus accumbens; nCx: neocortex; OB: olfactory bulb; Oc: occipital cortex;
on: olfactory nerve; opn: optic nerve; OT: olfactory tubercle; OV: olfactory
ventricle; Par: parietal cortex; PB: phosphate buffer; PBS: phosphate buffered
saline; PFA: paraformaldehyde; Pir: piriform cortex; poa: preoptic area;
Preoptic dz: preoptic differentiating zone; PRh: perirhinal cortex; PT:
pretectum; r: rostral; RGCs: retinal ganglion cells; Rs: retrosplenial cortex; RT:
room temperature; SC: superior colliculus; csc: commissure of superior
colliculus; SP: subplate; Spt: septum; St: striatum sta: subthalamic area; svz:
subventricular zone; svzo: olfactory subventricular zone; S1: primary
somatosensory cortex; t: temporal; Thal: thalamus; v: ventral; vb: vitreous
body VM: ventral mesencephalon; vThal: ventral thalamus; V3: third ventricle;
V3 ne: neuroepithelium of the third ventricle; V4: fourth ventricle; V4 ne:
neuroepithelium of the fourth ventricle; wt: wild type
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